A Phase 2/3, multicenter, randomized open-label study of zanzalintinib vs everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors

Phase

Phase II/III Clinical Trial

Trial Number

06943755

Trial Status

OPEN